Seeking Alpha
28 Jul 2026, 21:29 UTC · 8w ago
Verdict
Headline leans bullish. We score CMPS +0.90 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Compass Pathways has completed two successful Phase 3 trials and is currently executing a rolling FDA submission for COMP360.
More positive than 99% of claims this week
Eli Lilly's acquisition of Atai validates the psilocybin sector and increases the competitive landscape.
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 77% of claims this week
COMP360 has demonstrated encouraging data for PTSD and other potential indications beyond treatment-resistant depression.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 76% of relationship scores this week
[a_to_b] The text mentions Lilly's move for Atai as a validation of the field.
More positive than 35% of relationship scores this week
[mutual] Both companies are developing psilocybin treatments for depression and PTSD.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+26.7%
Price agrees with the score
$13.75 vs $10.85 close before publication (Jul 28) · not market-adjusted
CMPS chart →
